Literature DB >> 3487380

Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.

H F Dullens, S Schakenraad, A Oostdijk, W Vuist, M Van der Maas, W Den Otter.   

Abstract

The antitumor potency and specificity of syngeneic immune peritoneal exudate cells were tested. Groups of DBA/2 mice were immunized against syngeneic SL2 tumor cells. Then 6 days after the last immunization the antitumor potency, and the specificity of the immunization reaction was tested by injecting groups of the immunized mice with 10(3) to 5 X 10(7) DBA/2 derived L1210, L5178Y, P815 or SL2 tumor cells, and injecting immune peritoneal exudate cells into DBA/2 mice which had been injected 2 h earlier i.p. with 2 X 10(4) or 2 X 10(5) L1210, L5178Y, P815, or SL2 cells. Furthermore the tumor specific cytotoxicity in vitro of isolated immune (vs SL2) peritoneal macrophages was tested against L1210, L5178Y, P815, and SL2 cells. The "reciprocal" experiments (previous immunization against L1210, L5178Y, or P815 cells and 'challenge' with SL2) were also done. Finally, we tested the tumor-specific cytotoxicity of isolated immune peritoneal T-lymphocytes. It was shown that the rejection of tumor cells in previously immunized mice, the antitumor efficacy of the transferred immune peritoneal exudate cells and the in vitro cytotoxicity of purified immune peritoneal macrophages and lymphocytes, were tumor-specific reactions. That is only between the SL2 and L5178Y tumors were cross-reactions observed. However, this cross-reaction was not found at the level of cytotoxic T-cells. This suggests that cytotoxic T-cells and cytotoxic macrophages probably have different mechanisms of recognition of the specific tumor target cells. Treatment of macrophage monolayers, prepared from macrophages of immunized mice, with monoclonal anti-Thy-1 antibodies plus complement caused no decrease in cytotoxicity. This shows that macrophages can really express specific cytotoxicity. Tumoricidal macrophages probably obtain their tumor specificity through the activities of tumor-specific factors produced by sensitized T-cells.

Entities:  

Mesh:

Year:  1986        PMID: 3487380     DOI: 10.1007/BF00199122

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  39 in total

1.  Promotion of tumor growth in vivo by antimacrophage agents.

Authors:  R Keller
Journal:  J Natl Cancer Inst       Date:  1976-12       Impact factor: 13.506

2.  Therapy with allogeneic immune peritoneal cells.

Authors:  H F Dullens; W Den Otter
Journal:  Cancer Res       Date:  1974-07       Impact factor: 12.701

3.  Interaction of Bacillus Calmette--Guérin-activated macrophages and neoplastic cells in vitro II. The relationship of selective binding to cytolysis.

Authors:  P A Marino; D O Adams
Journal:  Cell Immunol       Date:  1980-08-15       Impact factor: 4.868

4.  Discrimination between macrophage-and NK-type tumoricidal activities via anti-asialo GM1 antibody.

Authors:  R Keller; T Bächi; K Okumura
Journal:  Exp Cell Biol       Date:  1983

5.  Tumor-bound immunoglobulins. I. Further analysis of the characteristics of binding of immunoglobulins to in vivo-grown tumor cells.

Authors:  G Dorval; I P Witz; E Klein; H Wigzell
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

6.  Phenotypic characterization of human T lymphocyte populations producing macrophage-activating factor (MAF) lymphokines.

Authors:  A Biondi; J A Roach; S F Schlossman; R F Todd
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

7.  Macrophage-activating factors from different T cell clones induce distinct macrophage functions.

Authors:  D Gemsa; K M Debatin; W Kramer; C Kubelka; W Deimann; U Kees; P H Krammer
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

8.  Lymphocyte-induced macrophage cytotoxicity. III. Induction of specific macrophage cytotoxicity is independent of lipopolysaccharide.

Authors:  R A de Weger; H van Loveren; J W de Groot; R Rangarajan; W den Otter
Journal:  Immunobiology       Date:  1986-04       Impact factor: 3.144

9.  The induction of lymphocytes with the capacity to render macrophages cytotoxic in an allogeneic murine system.

Authors:  R A De Weger; E Pels; W Den Otter
Journal:  Immunology       Date:  1982-11       Impact factor: 7.397

10.  Biological and antigenic similarities of murine interferon-gamma and macrophage-activating factor.

Authors:  L P Svedersky; C V Benton; W H Berger; E Rinderknecht; R N Harkins; M A Palladino
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more
  5 in total

1.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.

Authors:  H F Dullens; W Vuist; M Van der Maas; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Authors:  H F Dullens; R A De Weger; M Van der Maas; P J Den Besten; R J Vandebriel; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.

Authors:  J J Bergers; W Den Otter; J W De Groot; A W De Blois; H F Dullens; P A Steerenberg; D J Crommelin
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Cyclophosphamide modifies the induction kinetics but not cell types and cytotoxic mechanisms of antitumor cells elicited with OK-432 plus attenuated tumor cells.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.